Pharmacovigilance Study To Evaluate Safety Of AVODART In Subjects With Benign Prostate Hyperplasia

Inclusion Criteria: * Subject should fulfil criteria for the subscription of AVODART as these are mentioned in the SPC * Subject should be diagnosed with benign prostate hyperplasia * Subject's prostate volume should be equal or greater than 30 cm3 Exclusion Criteria: * Known hypersensitivity to any of the AVODART compounds * Suffers from a serious illness which either is not properly controlled or as per investigator´s judgment could interfere with the subject´s compliance into the trial * Receives treatment with enzyme inhibitors CYP3A4 and CYP3A5. * History of severe liver failure